5 days Ago By Paul Lee
LEESOL, a healthcare startup specializing in electronic pharmaceutical platforms for the prevention, diagnosis, and treatment of neurological disorders, announced on Nov. 18 that its wearable sleep management device, Sleepisol Lite, has won the prestigious CES 2025 Innovation Award. This award recognizes LEESOL’s cutting-edge technological expertise and design innovation on the global stage.
The CES Innovation Awards, presented annually by the Consumer Technology Association (CTA), honor products that stand out for their groundbreaking technology and forward-thinking design. The recognition of Sleepisol Lite highlights its innovative potential in the global sleep and healthcare markets. Sleepisol Lite, which won in the Beauty & Personal Care category, is an ergonomic headband-style wearable device that uses neuromodulation technology to stimulate specific areas of the brain, improving both sleep quality and concentration.
The device’s core feature is cranial electrotherapy stimulation (CES), which uses microcurrents to promote deep sleep and enhance cognitive focus. The device applies patented technology utilizing transcranial alternating current stimulation (tACS), which combines burst signals that penetrate the skin barrier with sleep-inducing frequencies to create a more effective sleep environment. A clinical study conducted at Seoul National University Hospital with 60 insomnia patients showed sleep quality improvement and a 175% improvement in Beck Depression Inventory-II (BDI-II) scores, which are closely related to sleep, indicating positive impacts on sleep and mental health.
The results of this study were published in the Journal of Sleep Research and the Journal of Affective Disorders in 2023. Weighing just 33 grams, the Sleepisol Lite features a simple slide-button operation and can be used continuously for up to 8 months without recharging, thanks to its built-in AAAA battery. This user-friendly design allows individuals to manage their sleep and mental health conveniently and consistently, regardless of location.
A LEESOL spokesperson commented, "Winning the CES Innovation Award is a significant milestone for us, as it recognizes our innovative technology and ergonomic design on an international platform. We are grateful to the researchers and developers who made this technology a reality. This achievement will help set new standards in sleep management and mental health, and we are excited to expand quickly into global markets.
" According to the World Health Organization (WHO), approximately 30% of the global population suffers from sleep disorders. LEESOL aims to be at the forefront of providing solutions to this global challenge, with its Sleepisol series of devices improving sleep quality, mental health, and overall well-being, enhancing the quality of life for users. Recently, LEESOL raised 4 billion KRW in Series A funding and secured up to 1.
7 billion KRW in research and development funding through the Ministry of Small and Medium-sized Enterprises and Startups' DeepTech TIPS program. Additionally, Sleepisol Plus was named a finalist in the 2024 IDEA Design Awards in the Medical & Health category..
